Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) EBITDA Margin (2020 - 2022)

Sonoma Pharmaceuticals (SNOA) has 3 years of EBITDA Margin data on record, last reported at 24.41% in Q4 2012.

  • For Q4 2012, EBITDA Margin rose 11764.0% year-over-year to 24.41%; the TTM value through Dec 2012 reached 66.47%, up 243048.0%, while the annual FY2012 figure was 58.7%, 78839.0% up from the prior year.
  • EBITDA Margin reached 24.41% in Q4 2012 per SNOA's latest filing, up from 29.41% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 26.33% in Q1 2011 and bottomed at 1131.05% in Q2 2010.
  • Average EBITDA Margin over 3 years is 210.26%, with a median of 29.88% recorded in 2011.
  • The widest YoY moves for EBITDA Margin: up 93982bps in 2012, down -5252bps in 2012.
  • A 3-year view of EBITDA Margin shows it stood at 97.28% in 2010, then grew by 4bps to 93.23% in 2011, then skyrocketed by 126bps to 24.41% in 2012.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 24.41% in Q4 2012, 29.41% in Q3 2012, and 8.52% in Q2 2012.